Consistent with our findings, erlotinib combined with pertuzumab has been shown to surpass single therapy in inhibiting tumor activity in a NSCLC xenograft model with high EGFR protein expression (QG-56 cells) [30]. This evidence concerns the gene EGFR and neoplasm.